PowderMed Launched in Spin Out of Powder Injection DNA Vaccine Programmes From Chiron Vaccines

17-May-2004

Oxford, UK - PowderMed Ltd (PowderMed), a new company focussing on the development of therapeutic DNA vaccines, was officially launched today. The Company has been created through a spin out of the powder injection DNA Vaccines technology from Chiron Vaccines, a business unit of Chiron Corporation, backed by £20 million ($34.5 million; EUR30 million) in venture capital from a syndicate of leading Life Science investors. Simultaneous with launch, PowderMed has announced that it has enhanced a deal with GlaxoSmithKline (GSK) under which GSK will gain additional licences to the PowderJect® powder injection technology in the field of oncology and PowderMed will acquire two former GSK DNA vaccine programmes that are based on this technology. PowderMed also announces that five new therapeutic vaccines, each using the proprietary PowderJect® DNA powder injection technology, would progress into clinical development within the next two years.

Dr Clive Dix, CEO of PowderMed and the former head of PowderJect's R&D, led the spin out. PowderMed's new shareholders include Schroder Ventures Life Sciences, Advent Venture Partners, Abingworth Management Ltd. and Oxford Bioscience Partners, with Chiron Vaccines retaining a minority equity stake. As part of the spin out, PowderMed has acquired all rights to vaccine applications of the PowderJect® technology and the related therapeutic DNA vaccine programmes. The Company will occupy purpose designed development facilities in Oxford UK, which it takes over from Chiron Vaccines.

Initially, PowderMed will focus on applying its PowderJect technology to the development of therapeutic DNA vaccines. Therapeutic vaccines are a new class of product, which harness the immune system in order to produce a therapeutic effect. PowderMed's lead preclinical programmes are all based on its proprietary PowderJect technology and are focused on the treatment of chronic viral diseases and cancer, namely genital herpes, hepatitis B, genital warts, HIV/AIDS and lung cancer.

Launching the Company, Dr Dix said: "PowderMed's technology is clinically validated and provides a unique ability to use the immune system to treat chronic diseases. Using this pioneering technology, we will be developing an exciting pipeline of therapeutic DNA vaccines. PowderMed with it's experienced development team starts its life well placed to become the leading therapeutic DNA vaccine company in the world."

Commenting on behalf of the investors, Tom Daniel, General Partner with Schroder Ventures Life Sciences said: "PowderMed enjoys many attractive qualities from its inception, including a broad pipeline of advanced therapeutic programmes, an experienced management team who've worked together on these programmes for years, and an excellent industrial partner in GSK. We are delighted to be backing the business and to be doing so in the company of a great syndicate of investors.

" Commenting on the agreement, John Lambert, President of Chiron Vaccines, said: "We believe that powder injection has great potential as a novel vaccine delivery technique, Although the technology platform does not fit with Chiron Vaccines' R&D pipeline, we are pleased that its development will continue under the stewardship of PowderMed, with its experienced management team and first class financial backers."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances